Evidence map›Paper›PMID 38374311›Full record

ArticleMikrochimica acta2024

T790M mutation upconversion fluorescence biosensor via mild ATRP strategy and site-specific DNA cleavage of restriction endonuclease.

Yanju Liu, Liang Guo, Mengyuan Hou, Haiyang Gao, Yuanmeng Ke, Huaixia Yang, Fuchun Si

Abstract read
PubMed Publisher
In one paragraph

Article in Mikrochimica acta, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Yanju LiuPharmacy College, Henan University of Chinese Medicine, Zhengzhou, 450046, People's Republic of China.
Liang GuoPharmacy College, Henan University of Chinese Medicine, Zhengzhou, 450046, People's Republic of China.
Mengyuan HouPharmacy College, Henan University of Chinese Medicine, Zhengzhou, 450046, People's Republic of China.
Haiyang GaoPharmacy College, Henan University of Chinese Medicine, Zhengzhou, 450046, People's Republic of China.
Yuanmeng KePharmacy College, Henan University of Chinese Medicine, Zhengzhou, 450046, People's Republic of China.
Huaixia YangPharmacy College, Henan University of Chinese Medicine, Zhengzhou, 450046, People's Republic of China. yanghuaixia886@163.com.ORCID http://orcid.org/0000-0001-5077-4002
Fuchun SiPharmacy College, Henan University of Chinese Medicine, Zhengzhou, 450046, People's Republic of China. sifc2000@hotmail.com.
First Affiliated Hospital of Henan University · CNHenan University of Traditional Chinese Medicine · CN

Funding

the project of tackling of key scientific and technical problems in Henan Province 202102310149the project of tackling of key scientific and technical problems in Henan Province 232102321119
6 · The paper itself

Abstract

A unique combination of a specific nucleic acid restriction endonuclease (REase) and atom transfer radical polymerization (ATRP) signal amplification strategy was employed for the detection of T790M mutations prevalent in the adjuvant diagnosis of lung cancer. REase selectively recognizes and cleaves T790M mutation sites on double-stranded DNA formed by hybridization of a capture sequence and a target sequence. At the same time, the ATRP strategy resulted in the massive aggregation of upconverted nanoparticles (UCNPs), which significantly improved the sensitivity of the biosensor. In addition, the UCNPs have excellent optical properties and can eliminate the interference of autofluorescence in the samples, thus further improving the detection sensitivity. The proposed upconversion fluorescent biosensor is characterized by high specificity, high sensitivity, mild reaction conditions, fast response time, and a detection limit as low as 0.14 fM. The performance of the proposed biosensor is comparable to that of clinical PCR methods when applied to clinical samples. This work presents a new perspective for assisted diagnosis in the pre-intervention stage of tumor diagnostics in the early stage of precision oncology treatments.

Indexed as

Biosensing TechniquesLung NeoplasmsDNA CleavageDNA Restriction EnzymesErbB ReceptorsHumansLimit of DetectionMutationPolymerizationPrecision MedicineProtein Kinase InhibitorsDNA Restriction EnzymesErbB ReceptorsProtein Kinase InhibitorsAtom transfer radical polymerizationFluorescence biosensorRestriction endonucleaseT790MUpconversion nanoparticles

Identifiers

PMID38374311
OpenAlexW4391968333

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.